AKROSWISS
17.5.2021 10:02:05 CEST | Business Wire | Press release
Akroswiss is developing an innovative and patented Midazolam-based nasal spray to treat patients suffering from claustrophobia and epileptic seizures. In April, the Swiss start-up has raised several million Swiss Franc in a strategic seed funding round. The funding will fuel R&D to fulfill EMAs requirements to obtain EU marketing authorization for the product.
The majority of Akroswiss’ new funding came from financial investors, the family investment group Linsi, with radiologist and primary user Prof. Dr. med. Bernhard Schuknecht as well as existing investor Walter P. Hölzle also participating in the round. The board has therefore, been extended to seat the new investor groups. Marc Froehlich, former pharma strategy consultant, will operationally lead the company in the role of CEO. Akroswiss will use the new funds to further product development, conduct clinical studies, and initiate the medical device regulatory process to complement EMA’s requirements for data package submission.
Prof. Dr. med. Bernhard Schuknecht highlights: “In our radiology institute Midazolam based nasal spray has been applied for many years during diagnostic examinations. The spray enables adequate resolution of anxiety and sedation and therefore, facilitates patients’ examinations. Akroswiss bi-dose spray is easy to administer and more hygienic than any other solution. Relief of anxiety by endonasal administration is a safe, effective route to improve patients’ comfort and image quality without the necessity of an intravenous line.
An additional advantage of Akroswiss bi-dose nasal spray is the emergency endonasal administration of midazolam in patients with a sudden onset seizure. Thus, a safe route of endonasal administration on an emergency basis may effectively prevent potential harmful injuries and progression into a potential life-threatening seizure status.
To make this product available for more patients in need, a European marketing authorization is required. I believe Akroswiss and its team are best positioned to reach this within reasonable time.”
Akroswiss has successfully developed and tested a unique Bi-dose nasal drug delivery device for Midazolam with a first-class 360° functionality. The development of these Midazolam medicines comes in two independent indications: (1)Product for premedication ahead of diagnostic and therapeutic interventions against claustrophobia and restlessness, (2) product for the rescue treatment in epileptic seizure patients.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210517005059/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Niagen Bioscience Receives Exclusive U.S. FDA Rare Pediatric Disease (RPD) Designation and European Medicines Agency Orphan Medicinal Product Designation (OMPD) for NB4168 for the Treatment of Ataxia Telangiectasia (A-T)13.7.2026 14:32:00 CEST | Press release
Regulatory recognition in the United States and Europe supports the development of NB4168, a novel small molecule candidate for a rare pediatric disease with no approved treatments Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that the U.S. Food & Drug Administration (FDA) granted Rare Pediatric Disease (RPD) Designation for its proprietary lead small molecule drug candidate NB4168 for the treatment of Ataxia Telangiectasia (A-T). NB4168 is an oral small molecule therapy engineered to deliver substantially greater nicotinamide riboside (NR) exposure than conventional NR while maintaining a differentiated pharmacokinetic and safety profile. In addition, the European Medicines Agency (EMA) has granted Orphan Medicinal Product Designation (OMPD) to NB4168 for the treatment of A-T, providing regulatory recognition in the European Union and further supporting the Company'
SLB OneSubsea Awarded EPC Contract for Eni’s Baleine Phase 3 Project Offshore Côte d'Ivoire13.7.2026 14:00:00 CEST | Press release
Integrated subsea production system and local capabilities enable accelerated deepwater development Global energy technology company SLB (NYSE: SLB) announced today that its OneSubsea™ joint venture has been awarded a major multi-well engineering, procurement, and construction (EPC) contract by Eni for Phase 3 of the deepwater Baleine project offshore Côte d’Ivoire. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260712734539/en/ SLB OneSubsea™ joint venture has been awarded a major multi-well engineering, procurement, and construction (EPC) contract by Eni for Phase 3 of the deepwater Baleine project offshore Côte d’Ivoire. Under the contract, SLB OneSubsea will deliver complete subsea production systems (SPS) for 13 wells, reinforcing its role as a core technology and execution partner on one of the most strategically significant offshore developments currently underway in the region. The EPC scope includes subsea trees, um
HistoSonics Receives CE Mark, Unlocking Access Across Europe and Accelerating Global Commercialization of the Edison® Histotripsy Platform13.7.2026 14:00:00 CEST | Press release
HistoSonics, today announced that the company has received CE Mark approval in Europe for its Edison® System, enabling commercialization of the company’s non-invasive histotripsy technology in Europe and other markets that recognize the CE Mark. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260713505048/en/ HistoSonics Edison® Histotripsy System The Edison System is a novel, non-invasive, image guided platform that is intended for the destruction of liver tumors, including the partial or complete destruction of unresectable liver tumors. It uses the mechanical properties of focused ultrasound, called histotripsy, to liquefy and destroy unwanted tissue and tumors in a single procedure without the need for invasive procedures or radiation, and with potentially fewer side effects than traditional therapies. CE Mark approval follows an increasing number of regulatory clearances and was supported by a growing body of clinical ev
Esri Introduces ArcGIS Velocity for ArcGIS Enterprise to Power Real-Time GIS Operations13.7.2026 14:00:00 CEST | Press release
ArcGIS Velocity Brings Real-Time Data Ingestion, Analysis, and Automated Alerting to ArcGIS Enterprise Deployments Esri announces that ArcGIS Velocity is now available for ArcGIS Enterprise, enabling real-time data analytics and automated actions in self-hosted environments. This capability’s new deployment unifies real-time workflows across ArcGIS Online and ArcGIS Enterprise. This update benefits organizations across industries: public safety, transportation, logistics, and more. Esri, the global leader in location intelligence, has released for general availability ArcGIS Velocity for ArcGIS Enterprise for self-hosted deployments on Windows and Linux. This enables organizations to leverage Velocity from secure on-premises and private cloud environments. Available as software as a service (SaaS) for ArcGIS Online and now for self-hosted environments in ArcGIS Enterprise, Esri’s next-generation geospatial capability delivers real-time analytics on streaming, Internet of Things (IoT),
Agenus Announces Oversubscribed Private Placement of Up to $340 Million to Advance Registrational ROBBIN Trial of Neoadjuvant BOT+BAL in MSS Colon Cancer13.7.2026 12:00:00 CEST | Press release
$85M upfront financing, along with up to $255 million upon exercise of purchase warrants, is expected to fund ROBBIN1, Agenus' registrational Phase 3 trial of neoadjuvant botensilimab and balstilimab (BOT+BAL) in microsatellite-stable (MSS) colon cancer Transaction is structured to fund Agenus through key value-inflection points, including interim topline pathologic response data and interim and final event-free survival (EFS) analyses, with proceeds to fund Agenus operations through year-end 2031, assuming full warrant exercise ROBBIN target population in MSS colon cancer represents a >$7 billion addressable annual sales opportunity in the US for which no new therapies have been approved in over 20 years2,3 To focus resources on the neoadjuvant opportunity, Agenus is discontinuing financial support for the ongoing BATTMAN Phase 3 study in late-line metastatic MSS colorectal cancer Company to host conference call and webcast today at 8:30 a.m. ET Agenus Inc. (Nasdaq: AGEN), a leader in
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom